by Market Overview:
Preeclampsia diagnostic products offer early detection of risks associated with high blood pressure during pregnancy. These include blood and urine tests that help identify proteins and detect changes indicating potential preeclampsia.
The Preeclampsia Diagnostics market is estimated to be valued at US$ 1,587.53 Mn or Mn in 2023 and is expected to exhibit a CAGR of 11.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the preeclampsia diagnostics market is the rising adoption of novel biomarkers for early diagnosis. Biomarkers such as placental growth factor (PIGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and endoglin have shown great potential in predicting the onset of preeclampsia. Ongoing clinical trials are exploring the use of these novel biomarkers to develop accurate diagnostic tests for early detection of preeclampsia. This is expected to simplify monitoring and management of high-risk pregnancies.
SWOT Analysis
Strength: The preeclampsia diagnostics market has high growth prospects owing to the increasing cases of preeclampsia among pregnant women globally. The diagnostics tests help detect the condition at an early stage and enable timely treatment.
Weakness: Lack of awareness about preeclampsia in low and middle-income countries limit the adoption and potential growth of diagnostics tests. High cost of advanced diagnostics solutions also restricts their widespread use.
Opportunity: The development of novel and affordable point-of-care testing solutions provides an opportunity to increase diagnostics penetration in resource-poor settings. Growing research activities to develop efficient predictive and prognostic diagnostics present lucrative growth prospects.
Threats: Stringent regulatory approval process and intense competition from alternative therapies pose significant threats. Reimbursement issues also challenge the market growth to some extent.
Key Takeaways
The Global Preeclampsia Diagnostics Market Size is expected to witness high growth, exhibiting CAGR of 11.8% over the forecast period, due to increasing cases of preeclampsia among pregnant women. North America dominates the market owing to the presence of advanced healthcare infrastructure and high awareness about preeclampsia diagnostics.
Regional analysis: North America dominated the global market in 2023 and is expected to continue its dominance over the forecast period. This can be attributed to rising healthcare expenditure, growing awareness about preeclampsia, and increasing adoption of advanced diagnostic technologies in the region. Asia Pacific is anticipated to exhibit the fastest growth rate during the forecast period owing to growing population, improving healthcare infrastructure and rising medical tourism in developing countries such as India and China.
Key players: Key players operating in the preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc. These players are focusing on new product launches, geographic expansion and mergers & acquisitions to garner greater market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
